All In Biotech

Drug Trial Radar · NCT07202546

A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of Oral VH4524184 Coadministered With Emtricitabine and Tenofovir Alafenamide in Treatment Naive Viremic Persons With HIV-1 (INNOVATE Study)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Feb 11, 2026

Primary completion

Oct 28, 2027

Study completion Jul 9, 2032

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Oct 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC/TAF), to a standard HIV treatment called dolutegravir and lamivudine (DTG/3TC). The purpose of the study is to provide data on the long-term antiviral activity of the VH4524184 and provide information regarding dosing formulation for further evaluations.

Conditions

  • HIV Infections

Interventions

  • VH4524184Drug

    Oral tablet will be administered.

  • Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tabletsDrug

    Oral table will be administered.

  • Dolutegravir / Lamivudine (DTG/3TC)Drug

    Oral tablets will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Suppression (<50 copies/millilitre) as per FDA Snapshot MethodologyTime frame: At Month 12

Locations

125 sites in 14 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bakersfield, California · Recruiting

  • GSK Investigational Site

    Palm Springs, California · Recruiting

  • GSK Investigational Site

    West Hollywood, California · Recruiting

  • GSK Investigational Site

    Aurora, Colorado · Recruiting

  • GSK Investigational Site

    New Haven, Connecticut · Recruiting

  • GSK Investigational Site

    Ft. Pierce, Florida · Recruiting

  • GSK Investigational Site

    Hollywood, Florida · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Miami Gardens, Florida · Recruiting

  • GSK Investigational Site

    Oakland Park, Florida · Recruiting

  • GSK Investigational Site

    Orlando, Florida · Recruiting

  • GSK Investigational Site

    Orlando, Florida · Recruiting

  • GSK Investigational Site

    West Palm Beach, Florida · Recruiting

  • GSK Investigational Site

    Atlanta, Georgia · Recruiting

  • GSK Investigational Site

    Macon, Georgia · Recruiting

  • GSK Investigational Site

    Chicago, Illinois · Recruiting

  • GSK Investigational Site

    Louisville, Kentucky · Completed

  • GSK Investigational Site

    Columbia, Missouri · Recruiting

  • GSK Investigational Site

    Kansas City, Missouri · Recruiting

  • GSK Investigational Site

    Omaha, Nebraska · Recruiting

  • GSK Investigational Site

    Hackensack, New Jersey · Recruiting

  • GSK Investigational Site

    Newark, New Jersey · Recruiting

  • GSK Investigational Site

    Albany, New York · Recruiting

  • GSK Investigational Site

    Manhasset, New York · Recruiting

  • GSK Investigational Site

    Charlotte, North Carolina · Recruiting

  • GSK Investigational Site

    Durham, North Carolina · Recruiting

  • GSK Investigational Site

    Greensboro, North Carolina · Recruiting

  • GSK Investigational Site

    Wilmington, North Carolina · Recruiting

  • GSK Investigational Site

    Cincinnati, Ohio · Recruiting

  • GSK Investigational Site

    Bellaire, Texas · Recruiting

  • GSK Investigational Site

    Dallas, Texas · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Longview, Texas · Recruiting

  • GSK Investigational Site

    Seattle, Washington · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, Argentina · Recruiting

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.